Figure 1.

Effect of chronic low‐dose aspirin treatment on colon tumor formation and inflammation in the AOM/DSS model. (A) Schematic representation of the AOM/DSS and aspirin treatment protocol. (B) Tumor number, (C) tumor size; and (D) plasma TXB₂ concentration of mice (n = 5/group) following 12 wks of aspirin administration. (E and F) Colon length (E, n = 5/group) and disease activity index (F, n = 9/group) of control and aspirin‐treated mice. (G and J) Representative images of immunohistochemical staining for the macrophage marker F4/80 (G) and the inflammatory marker iNOS (J) of colon sections (magnification ×100) and quantification of the number of positive cells from control and aspirin‐treated mice (n = 5/group). (H and I) IL‐1β (H) and IL‐6 (I) concentration in supernatants of colon explant cultures of control and aspirin‐treated mice (n = 5/group). *P < .05, **P < .01, ***P < .001 by unpaired Student's t test